tbuckley/cabot-search huggingface dataset:
Effects of heparin on plasma tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in patients with acute myocardial infarction (AMI) Shaker A. Mousa, Jeffrey M. Bozarth, Marc Cohen, Michael F. Wilson, Mofid N. Khalil-Ibrahim. DuPont Pharmaceuticals co., Wilmington, DE, Kaleida Health &amp; univ. of New York, Buffalo, NY
Journal: Journal of the American College of Cardiology (2001)
A simple ECG algorithm derived by pace mapping along the border of scared myocardium may more accurately identify the exit site of unstable postinfarcton ventricular tachycardia Koji Azegami, Mauricio Arruda, Martin C. Burke, Douglas E. Kopp, John G. Kall, Albert C. Lin, David J. Wilber. University of Chicago, Chicago, IL
Journal: Journal of the American College of Cardiology (2001)
This Week in &lt;emph&gt;JAMA&lt;/emph&gt;
Journal: JAMA (2010)

A Piece of My Mind"Even as I tried to calmly deliberate the options in front of me, I could feel my objectivity slipping further away, only to be replaced with a terrified patient who was quickly losing the ability to think straight."From "The Hike." SEE PAGE 134 Medical News & PerspectivesScientists are attempting to develop better tools for early identification of individuals at risk for developing schizophrenia, as well as interventions to help prevent the disorder in such at-risk persons.
Comparison of rotational atherectomy versus PTCA with or without stenting in cacified lesions: In-hospital and 6-month outcome Mandeep Singh, Verghese Mathew, Ryan J. Lennon, John F. Bresnahan, Daniel J Tiede, Charanjit S Rihal. Mayo Clinic, Rochester, MN
Journal: Journal of the American College of Cardiology (2001)
Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa
Authors: Samuel Der Sarkissian, Schapoor Hessam, Joslyn S. Kirby, Michelle A. Lowes, Dillon Mintoff, Haley B. Naik, Hans Christian Ring, Nisha Suyien Chandran, John W. Frew
Journal: JAMA Dermatology (2022)

The identification and validation of biomarkers in hidradenitis suppurativa (HS) has potential to improve the understanding and management of this chronic, burdensome disease.To systematically identify all known HS biomarkers, categorize them by biomarker type, and critically evaluate their validity according to established criteria.Eligibility criteria for this review (PROSPERO Registration 230830) included randomized clinical trials, uncontrolled clinical trials, cohort studies, case-control studies, and other observational studies with no restrictions of patient age, sex, race or ethnicity, or language of publication up until December 31, 2020. All articles were categorized into biomarker type, defined using the US Food and Drug Administration Biomarkers, Endpoints, and other Tools (BEST) glossary. Assessment of each identified biomarker was undertaken in line with the US Food and Drug Administration and European Medicines Agency guidelines for the validation of proposed biomarkers. Assessment of the strength of overall data regarding individual biomarkers was undertaken using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach.A total of 3953 nonduplicate articles were screened, of which 1429 articles were retrieved based on the include/exclusion criteria applied. After full-text screen and data extraction, 106 articles were included in this review. The evidence of strength of 6 categories of biomarkers (susceptibility/risk, diagnostic, monitoring, predictive, prognostic, and pharmacodynamic/response biomarkers) was assessed using GRADE criteria. A total of 48 biomarkers were identified with a minimum GRADE rating of moderate. Only 1 diagnostic (serum IL-2R), 1 monitoring (dermal Doppler vascularity), and 2 predictive biomarkers (epithelialized tunnels and positive family history of HS) achieved a GRADE rating of high. None of the identified biomarkers had sufficient clinical validity to be recommended for routine use in the clinical setting.Major barriers to the identification, validation, and introduction of routine biomarkers in the management of HS include lack of independent biomarker validation studies (especially assumption-free "omics"-based techniques); insufficient assessment of collinearity between identified or proposed biomarkers; and a lack of routine integration of biomarkers into the structure of clinical trials. International consensus among researchers, clinicians, and pharmaceutical stakeholders is required to standardize goals and methods and encourage biomarker integration into future HS clinical trials. This systematic review presents a number of priorities for near-term future research to overcome such barriers and limitations of biomarkers in HS.
Recent events of special interest to medical education
Authors: R. L. Egan
Journal: JAMA (1986)

The EDUCATION ISSUE of<i>JAMA</i>traditionally has included a review of events that have had an impact on medical education. Over the past several years, the events reviewed were those that sustained or improved the quality of medical education. At this point in the history of US medical education, there are several factors at work that separately and collectively are producing trends that threaten the clinical base, which has become an integral part of our system of medical education. The public concern for cost containment in health care has led to the operation of some hospitals by professional management firms and to other hospitals becoming investor-owned with a vertically integrated system of health care delivery. The corporate search for less expensive health insurance for employees has produced "competition" for patients and the formation of health maintenance organizations (HMOs) and preferred provider organizations (PPOs). Cost containment at the federal level has
Medical audit JCAH-style. A negative view
Authors: E. W. Rosenberg
Journal: JAMA (1977)

THE MEASUREMENT of medical care against objective, predetermined, explicit criteria—the so-called medical audit—has turned into an every-month, if not every-day, procedure at most American hospitals. The major credit for changing medical audit from theory to reality clearly belongs to the Joint Commission for the Accreditation of Hospitals (JCAH), which has made such activities a requirement for accreditation. <h3>The Rise of PEP</h3> In a short time, the JCAH has been able to accomplish more than had medical educators or Professional Service Review Organizations (PSRO). This achievement is due to the efforts of JCAH in designing, supplying, and promoting an appealing, prepackaged, ready-to-go system of medical audit, the Performance Evaluation Procedure (PEP).<sup>1</sup> Not only did PEP offer a fully prepared and relatively easy-to-install medical audit, it also came buttressed by a well-organized and effectively managed series of seminars where hospital trustees, administrators, and physicians were taught how to install the system
Oral methadone maintenance techniques in the management of morphine-type dependence
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Metoprolol and carvedilol similarly reduce nitrate tolerance in healthy men Hans P. Brunner-La Rocca, Alexandra Meier, Christoph Scharf, Ruth Schindler, Erwin Oechslin, Bruno Fink, J�rgen Armbrecht, Beatrix Lutiger, Eberhard Bassenge, Wolfgang Kiowski. Cardiology, University Hospital, Zurich, Switzerland, University of Freiburg, Freiburg, Germany
Journal: Journal of the American College of Cardiology (2001)
Lassa fever and global health security
Authors: None The Lancet Infectious Diseases
Journal: The Lancet Infectious Diseases (2018)

Seeing the terms "viral haemorrhagic fever" and "west Africa" together will conjure grave images for our readers. The 2013–16 Ebola virus disease epidemic was an unprecedented event, not only in terms of illness and death but also for showing the frailties of international preparedness for infectious disease outbreaks. Nigeria is in the midst of its largest ever outbreak of Lassa fever. At the same time, a mooted 80% cut to the US CDC's Global Health Security Agenda threatens to create a vacuum in essential epidemic mitigation activities.
International Congress on Endocrinology of the Breast
Journal: JNCI Journal of the National Cancer Institute (1984)

International Congress on Endocrinology of the Breast JNCI: Journal of the National Cancer Institute, Volume 72, Issue 1, January 1984, Page 200, https://doi.org/10.1093/jnci/72.1.200-d Published: 01 January 1984
TCT-204 Application of the “Hybrid Approach” to Chronic Total Occlusions in a Contemporary Multicenter US Registry
Authors: Rohan V. Menon, Georgios Christopoulos, Dimitri Karmpaliotis, R. Michael Wyman, Khaldoon Alaswad, William Lombardi, J. Aaron Grantham, Nicholas Lembo, David Kandzari, James Lee, Kalynych Anna, Harold Carlson, Santiago Garcia, Subhash Banerjee, Craig Thompson, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2014)
A signature of saliva-derived exosomal small RNAs as predicting biomarker for esophageal carcinoma: a multicenter prospective study
Authors: Kai Li, Yusheng Lin, Yichen Luo, Xiao Xiong, Lu Wang, Kameron Durante, Junkuo Li, Fuyou Zhou, Yi Guo, Shaobin Chen, Yuping Chen, Dianzheng Zhang, Sai-Ching Jim Yeung, Hao Zhang
Journal: Molecular Cancer (2022)

Abstract Background The tRNA-derived small RNAs (tsRNAs) are produced in a nuclease-dependent manner in responses to variety of stresses that are common in cancers. We focus on a cancer-enriched tsRNA signature to develop a salivary exosome-based non-invasive biomarker for human esophageal squamous cell carcinoma (ESCC). Methods Cancer-enriched small RNAs were identified by RNA sequencing of salivary exosomes obtained from ESCC patients ( n = 3) and healthy controls ( n = 3) in a pilot study and further validated in discovery cohort ( n = 66). A multicenter prospective observational study was conducted in two ESCC high-incidence regions ( n = 320 and 200, respectively) using the newly developed biomarker signature. Results The tsRNA (tRNA-GlyGCC-5) and a previously undocumented small RNA were specifically enriched in salivary exosomes of ESCC patients, ESCC tissues and ESCC cells. The bi-signature composed of these small RNAs was able to discriminate ESCC patients from the controls with high sensitivity (90.50%) and specificity (94.20%). Based on the bi-signature Risk Score for Prognosis (RSP), patients with high-RSP have both shorter overall survival (OS) (HR 4.95, 95%CI 2.90–8.46) and progression-free survival (PFS) (HR 3.69, 95%CI 2.24–6.10) than those with low-RSP. In addition, adjuvant therapy improved OS (HR 0.47, 95%CI 0.29–0.77) and PFS (HR 0.36, 95%CI 0.21–0.62) only for patients with high but not low RSP. These findings are consistent in both training and validation cohort. Conclusions The tsRNA-based signature not only has the potential for diagnosis and prognosis but also may serve as a pre-operative biomarker to select patients who would benefit from adjuvant therapy. Trial registration A prospective study of diagnosis biomarkers of esophageal squamous cell carcinoma, ChiCTR2000031507 . Registered 3 April 2016 - Retrospectively registered.
Risk for Newly Diagnosed Diabetes &gt;30 Days After SARS-CoV-2 Infection Among Persons Aged &lt;18 Years — United States, March 1, 2020–June 28, 2021
Authors: Catherine E. Barrett, Alain K. Koyama, Pablo Alvarez, Wilson Chow, Elizabeth A. Lundeen, Cria G. Perrine, Meda E. Pavkov, Deborah B. Rolka, Jennifer L. Wiltz, Lara Bull-Otterson, Simone Gray, Tegan K. Boehmer, Adi V. Gundlapalli, David A. Siegel, Lyudmyla Kompaniyets, Alyson B. Goodman, Barbara E. Mahon, Robert V. Tauxe, Karen Remley, Sharon Saydah
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

The COVID-19 pandemic has disproportionately affected people with diabetes, who are at increased risk of severe COVID-19.* Increases in the number of type 1 diabetes diagnoses (1,2) and increased frequency and severity of diabetic ketoacidosis (DKA) at the time of diabetes diagnosis (3) have been reported in European pediatric populations during the COVID-19 pandemic. In adults, diabetes might be a long-term consequence of SARS-CoV-2 infection (4-7). To evaluate the risk for any new diabetes diagnosis (type 1, type 2, or other diabetes) >30 days
Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.
Authors: Tara Elisabeth Seery, Chaitali Singh Nangia, Heidi Ann McKean, Leonard S. Sender, Paul Bhar, Sandeep K. Reddy, Patrick Soon-Shiong
Journal: Journal of Clinical Oncology (2022)

582 Background: Pancreatic cancer claimed an estimated 47,050 lives in the USA in 2020, with an expected median overall survival (OS) of 3 months in 3rd line. (Manax ASCO GI 2019), with no evidence of disease control in these late stage patients. We hypothesize that effective response against pancreatic cancer requires orchestration of both the innate and adaptive immune system to accomplish immunogenic cell death with survival benefit. Herein we report the first results of a novel combination immunotherapy protocol of low-dose chemoradiation, cytokine-induced NK and T cell activation via N-803 (an IL-15 cytokine superagonist), and allogeneic off-the-shelf PDL1-targeted high-affinity NK cell (PDL1 t-haNK) infusion. Methods: We report data from a multi-center study, on 55 3rd line or greater, subjects treated with low dose, chemo radiation Nab-paclitaxel (100 mg/ m2 IV), Gemcitabine (600 mg/m2 IV); Cyclophosphamide (50 mg PO BID) and low dose SBRT. This induction immuno-modulation therapy to induce DAMPs was followed with investigational agents activating the innate and adaptive systems: Aldoxorubicin (150 mg/m2 IV), N-803, an IL-15 superagonist (15 μg/kg SC) and PD-L1 t-haNK (̃2 × 109cells/dose IV). Prophylactic G-CSF or EPO was not allowed. All treatments were administered on an outpatient basis. Results: As of submission, median follow-up is 3.9 months. Median age 62, M:F ratio 35:20. ECOG 0-1,92%. 41/55 (75%) subjects reported a grade ≥3 AE related to the chemo radiation, anemia 44%, neutropenia 24%, thrombocytopenia 11%, all others &lt; 10%. SAEs attributed to investigational agents were reported in 5/55 (9%) patients. Of the 44 patients evaluable at 3 months to date, the OS is 81.8% (36/44), 95% CI: 67.3%, 91.8%. The disease control rate of 47 evaluable patients is 36.2% (17/47) 95% CI 22.7%,51.5%. No treatment related deaths have occurred. Treatment is ongoing for 16 subjects, with 14 months as the longest duration on therapy to date. Median OS not yet reached with 28/55 alive to date. Median PFS is 2.4 months (95% CI: 2.0, 3.7) and 36% of subjects not having progressed to date. Conclusions: Historical 3 month median OS in 3rd line metastatic pancreatic cancer patients has been exceeded. Early safety and promising efficacy is seen in QUILT 88 investigating a novel combination immunotherapy protocol of low-dose chemoradiation, N-803 and PDL1 t-haNK therapy. Updated data will be presented. Clinical trial information: NCT04390399.
Wortmannin blocks the carbachol-induced inhibition of L-type Ca current in mouse ventricular myocytes: Role of phosphatidylinositol 3 OH-kinase/AKT/nitric oxide in muscarinic regulation of Ca current Fuhua Chen, Meisheng Jiang, Shulan Ding, Lutz Birnbaumer. UCLA School of Medicine, Los Angeles
Journal: Journal of the American College of Cardiology (2001)
Ophthalmology
Authors: F. C. Blodi
Journal: JAMA (1980)

This year it seems appropriate to review three advances made in the basic aspects of ophthalmology that will be of great significance in our clinical work. <h3>Transplantation of Cultured Corneal Endothelium</h3> The corneal endothelium plays a primary role in determining the result of a keratoplasty. The transparency of the cornea depends on the activity of corneal endothelial cells. In the primate eye these endothelial cells have only a limited capability to repair defects; extensive endothelial wounds will result in edema and opacification of the corneal stroma. Corneal endothelial cells of various animals can now be cultured in a monolayer and kept alive through numerous passages.<sup>1</sup>The cells remain active. They can be transplanted as a layer onto the denuded back surface of the cornea of an animal of a different species. The cells remain viable, and the cornea remains clear. Even cultured vascular endothelium can be used for such
Correction
Journal: Hepatology (2008)

In the October 2007 article "Mutations in the MPV17 gene are responsible for rapidly progressive liver failure in infancy" by Wong, Brunetti-Pierri, et al. (HEPATOLOGY 2007;46:1218-1227), strike-through lines for cases 3 and 4 in Figure 1 are missing.Below is the corrected version of Figure 1: Additional corrections are as follows:• Page 1221, 2nd column, 1st sentence, "vastus lateralis of" should be removed.The correct sentence is: "Spectrophotometric analysis of the respiratory chain complexes was performed on liver samples from patients 2 (explant liver), 3 and 4, and in muscle (quadriceps femoris) from patients 1 and 4."• Page 1223, legend to Figure 2, the correct sentence should read as: "Case 4 (I) Side by side are hepatocytes with prominent lipid droplets and others with nonvacuolated, swollen coarsely granular cytoplasm.• Page 1224, last sentence should read as: ". . . of 3 and 9 nucleotides; each parent carries one of these mutations.
A proportionate response to H7N9
Authors: None The Lancet Infectious Diseases
Journal: The Lancet Infectious Diseases (2013)

Since Chinese authorities first reported on March 31, 2013, the emergence of a new form of influenza A virus—H7N9—causing human disease, there has been speculation as to whether this virus will be the agent of the next influenza pandemic. The H1N1 pandemic of 2009–10 was milder and caused far fewer deaths than were predicted when that virus first emerged. As a consequence, there is understandable scepticism when health authorities warn that the next pandemic might be just around the corner. However, given the severity of illness caused by H7N9 and its high case-fatality rate, a way must be found between vigilance and fear-mongering.
Thomas Jefferson: Scientist
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CHF severity and neurohormonal activation in a large international population with chronic heart failure enrolled in Val-HeFT Roberto Latini, Inder Anand, Serge Masson, Dianne Judd, Monica Salio, Gabriella Baldi, Robert Glazer, Dirk P. Spormann, Aldo P. Maggioni, Gianni Tognoni, Jay N. Cohn, on behalf of the Val-HeFT Investigators. Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, University of Minnesota, Minneapolis, MN
Journal: Journal of the American College of Cardiology (2001)
Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer
Authors: Vanessa F. Bonazzi, Olga Kondrashova, Deborah Smith, Katia Nones, Asmerom T. Sengal, Robert Ju, Leisl M. Packer, Lambros T. Koufariotis, Stephen H. Kazakoff, Aimee L. Davidson, Priya Ramarao-Milne, Vanessa Lakis, Felicity Newell, Rebecca Rogers, Claire Davies, James Nicklin, Andrea Garrett, Naven Chetty, Lewis Perrin, John V. Pearson, Ann-Marie Patch, Nicola Waddell, Pamela M. Pollock
Journal: Genome Medicine (2022)

Abstract Background Endometrial cancer (EC) is a major gynecological cancer with increasing incidence. It comprises four molecular subtypes with differing etiology, prognoses, and responses to chemotherapy. In the future, clinical trials testing new single agents or combination therapies will be targeted to the molecular subtype most likely to respond. As pre-clinical models that faithfully represent the molecular subtypes of EC are urgently needed, we sought to develop and characterize a panel of novel EC patient-derived xenograft (PDX) models. Methods Here, we report whole exome or whole genome sequencing of 11 PDX models and their matched primary tumor. Analysis of multiple PDX lineages and passages was performed to study tumor heterogeneity across lineages and/or passages. Based on recent reports of frequent defects in the homologous recombination (HR) pathway in EC, we assessed mutational signatures and HR deficiency scores and correlated these with in vivo responses to the PARP inhibitor (PARPi) talazoparib in six PDXs representing the copy number high/p53-mutant and mismatch-repair deficient molecular subtypes of EC. Results PDX models were successfully generated from grade 2/3 tumors, including three uterine carcinosarcomas. The models showed similar histomorphology to the primary tumors and represented all four molecular subtypes of EC, including five mismatch-repair deficient models. The different PDX lineages showed a wide range of inter-tumor and intra-tumor heterogeneity. However, for most PDX models, one arm recapitulated the molecular landscape of the primary tumor without major genomic drift. An in vivo response to talazoparib was detected in four copy number high models. Two models (carcinosarcomas) showed a response consistent with stable disease and two models (one copy number high serous EC and another carcinosarcoma) showed significant tumor growth inhibition, albeit one consistent with progressive disease; however, all lacked the HR deficiency genomic signature. Conclusions EC PDX models represent the four molecular subtypes of disease and can capture intra-tumor heterogeneity of the original primary tumor. PDXs of the copy number high molecular subtype showed sensitivity to PARPi; however, deeper and more durable responses will likely require combination of PARPi with other agents.